ArticleBMC microbiology2025
Characterization of AI-2/LuxS quorum sensing system in antibiotic resistance, pathogenicity of non carbapenemase-producing carbapenem-resistant Escherichia coli.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LuxS/AI-2 regulates phoP/phoQ by a non-canonical mechanism to enhance acid stress survival in Salmonella Typhimurium.PLoS pathogens · 2026Article
- Integrated Experimental and Computational Discovery of Repurposed and Novel Inhibitors TargetingJournal of pharmacy & bioallied sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a quorum sensing system, LuxS/AI-2 is closely associated with bacterial growth, biofilm formation, and virulence. As yet, it is not known how the luxS is associated with a diverse array of physiological activities in non- carbapenemase producing carbapenem resistant Escherichia coli (non-CP-CREC). The purpose of this study is to explore the characterization of AI-2/LuxS quorum sensing system in antibiotic resistance, pathogenicity of non-CP-CREC.
methodsA total of five non-CP-CREC isolates that did not have ompC and ompF deletions were collected from various clinical samples from January 2021 to December 2023. RT-qPCR was used to detect genes expression of luxS, acrA, acrB, tolC, mdtB, mdtC, mdtE, mdtF, ompA, ompX, IL-8, IL-6, and TNF-α. Homologous recombination was used to create the luxS knockout strain. Transcriptome sequencing was utilized to analyze gene expression changes before and after the luxS knockout. Biofilm formation was detected using crystal violet staining. Antimicrobial susceptibility test was used to determine drug resistance. Bacterial growth curves were used to detect the influence of the luxS on bacterial growth. A cell infection assay was used to detect the impact of the luxS on bacterial adhesion and the inflammatory response it induces.
resultsOur results indicated that the expression of the luxS was significantly elevated in non-CP-CREC strains compared to the carbapenem antibiotics sensitive E. coli (CSEC), with CREC229 exhibiting the most pronounced difference. Consequently, CREC229 was chosen for the development of the luxS knockout strain (CREC229△luxS). The deletion of the luxS did not impact the growth of non-CP-CREC. RNA sequencing analysis revealed that 82 genes were differentially expressed, with notable alterations observed in genes associated with biofilm formation regulation and outer membrane proteins in the ΔluxS strain. Our transcriptomic results show that the expression of bssS associated with biofilm formation is significantly reduced in the ΔluxS strain, which in turn reduces its capacity for biofilm formation. In addition, the luxS deletion increased the expression of adhesion-related genes, such as ompA and ompX, enhanced HCT-8 adherence to CREC229, and promoted the secretion of the inflammatory cytokine IL-6. In terms of bacterial resistance, the deletion of luxS increased the sensitivity of non-CP-CRECs to aminoglycoside antibiotics.
conclusionsLuxS/AI-2 quorum sensing systems can alter pathogenicity and resistance in several ways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.